Skip to Content

Novo Nordisk A/S ADR NVO

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Capital Allocation

PREMIUM

Large-Cap Biopharma Capital Allocation Supports Primarily Wide-Moat Industry

Damien Conover, CFA Sector Director

Analyst Note

| Damien Conover, CFA |

The majority of the large-cap biopharma firms have moats, but almost all the drugs currently sold by the group will face generic competition over the next two decades, making successful capital allocation (evaluated by our capital allocation methodology) critically important in securing the current strong moat ratings within the group. We believe the patent life of drugs (typically 20 years, but with many years used during development) makes the biopharma group particularly reliant on successful redeployment of capital because of the need to constantly reinvent drug portfolios. We view a key part of successful capital allocation at big biopharma companies as a combination of (1) sound internal research and development (both in magnitude of investment and strategically focused in innovative therapeutic areas) and (2) successful external acquisitions and partnerships. The combination of successful internal development and external deals allows the big biopharma industry to consistently reinvent product portfolios and secure economic moats, protecting high returns on invested capital.

Read Full Analysis

Company Profile

Business Description

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Contact
Novo Alle 1
Bagsvaerd, DK-2880, Denmark
T +45 44448888
Sector Healthcare
Industry Biotechnology
Most Recent Earnings Jun 30, 2021
Fiscal Year End Dec 31, 2021
Stock Type
Employees 46,574

Related